What this is
- How it works
- How it works isn't classified yet
- Tested for
- Acne Vulgaris
- Main trialPhase 2
- “This is a phase 2b, randomized, double-blind, vehicle-controlled clinical trial evaluating the efficacy, safety, and tolerability of B244 compared to vehicle in the treatment of moderate to severe acne vulgaris in adolescents and adults. Participants who meet the study entry criteria will be randomized in a 1:1 ratio to receive twice daily topical doses of B244 O.D. 5.0 or vehicle (control) for 12 weeks.”In the company’s words, NCT07866105 on ClinicalTrials.gov
Other drugs for Acne Vulgaris
- TrifaroteneGalderma R&D · Phase 3
- Cyproterone Acetate and Ethinyl EstradiolEurofarma Laboratorios S.A. · Phase 3
- DenifanstatSagimet Biosciences Inc. · Ascletis · Phase 3
- ClascoteroneZhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Phase 3
- Acne mRNA vaccineSanofi · Phase 1/2
- HB0043Huahai Pharmaceutical (Huaota) · Phase 1/2
Coming up1
- Aug 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Aug 2027 | Study to Determine Efficacy, Safety, and Tolerability of B244 as a Topical Spray in Subjects With Moderate to Severe Acne Vulgaris | |
| Phase 2/3Completed | 19 Jul 2017 | Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris | |
| Phase 2Completed | 25 Apr 2017 | A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure | |
| Phase 2Completed | 11 Feb 2019 | A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea | |
| Phase 2Completed | 27 Feb 2019 | Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis | |
| Phase 2Completed | 17 Jun 2019 | Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine | |
| Phase 2Completed | 10 Dec 2021 | B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis | |
| Phase 1/2Completed | 21 Dec 2018 | Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis | |
| Phase 1Completed | 18 May 2019 | A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026